NIKKEI 225
38,102.44 -712.12 (-1.83%) HANG SENG
17,936.12 -5.66 (-0.03%) CRUDE OIL
79.89 +1.44 (+1.84%) GOLD FUTURES
2,330.60 -18.50 (-0.79%) DOW
38,743.34 +154.18 (+0.40%) Bitcoin GBP
52,264.84 -118.41 (-0.23%)
NVO Jul 2024 105.000 put
- Investor's Business Daily
Top Weight-Loss Rivals Share This Risk After Eye-Popping Runs
Popular weight-loss drugs have boosted Novo Nordisk and Eli Lilly. After huge gains, the drugmakers' stocks now face this risk.
- Globe Newswire
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 17 June 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the programme initiat
- Fortune
Ozempic is 1,300% more expensive in the U.S. vs the U.K.—so the boss of Novo Nordisk is being hauled in front of Bernie Sanders to explain why
Novo's Danish CEO Lars Fruergaard Jørgensen will face the U.S. Senate in September to defend Wegovy's and Ozempic's eye-watering prices.
